ArticleBiochimica et biophysica acta2015
Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.
Article in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization.Molecular oncology · 2026Article
- 3-D biomechanics and epigenomics reveal atypical fibroblast responses in cardiometabolic disease.American journal of physiology. Heart and circulatory physiology · 2025Article
- SRSF5 regulates alternative splicing ofRNA biology · 2021Article
- MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.Journal of bioenergetics and biomembranes · 2021Article
- Mechanisms regulating DMTF1β/γ expression and their functional interplay with DMTF1α.International journal of oncology · 2021Article
- Survival of Lung Cancer Patients Dependent on the LOH Status forInternational journal of molecular sciences · 2020Article
- Post-Translational Regulation of ARF: Perspective in Cancer.Biomolecules · 2020Review
- c-MYB and DMTF1 in Cancer.Cancer investigation · 2019Review
- Translocations involving ETS family proteins in human cancer.Integrative cancer science and therapeutics · 2018Article
- Regulatory Network of ARF in Cancer Development.Molecules and cells · 2018Review
- Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.Cancer investigation · 2018Article
- Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.Genes · 2017Review
- Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.Cancer investigation · 2017Article
- From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.International journal of molecular sciences · 2017Review
- Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.International journal of cancer · 2017Review
- Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.International journal of cancer · 2016Review
- Novel Molecular Markers for Breast Cancer.Biomarkers in cancer · 2016Review
- Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016Article
- Haploinsufficient tumor suppressor genes.Advances in medicine and biologyArticle
- Aberrant Expression of p14Tumor & microenvironmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
The human DMTF1 (DMP1) transcription factor, a DNA binding protein that interacts with cyclin D, is a positive regulator of the p14ARF (ARF) tumor suppressor. Our earlier studies have shown that three differentially spliced human DMP1 mRNAs, α, β and γ, arise from the human gene. We now show that DMP1α, β and γ isoforms differentially regulate ARF expression and promote distinct cellular functions. In contrast to DMP1α, DMP1β and γ did not activate the ARF promoter, whereas only β resulted in a dose-dependent inhibition of DMP1α-induced transactivation of the ARF promoter. Ectopic expression of DMP1β reduced endogenous ARF mRNA levels in human fibroblasts. The DMP1β- and γ-isoforms share domains necessary for the inhibitory function of the β-isoform. That DMP1β may interact with DMP1α to antagonize its function was shown in DNA binding assays and in cells by the close proximity of DMP1α/β in the nucleus. Cells stably expressing DMP1β, as well as shRNA targeting all DMP1 isoforms, disrupted cellular growth arrest induced by serum deprivation or in PMA-derived macrophages in the presence or absence of cellular p53. DMP1 mRNA levels in acute myeloid leukemia samples, as compared to granulocytes, were reduced. Treatment of acute promyelocytic leukemia patient samples with all-trans retinoic acid promoted differentiation to granulocytes and restored DMP1 transcripts to normal granulocyte levels. Our findings imply that DMP1α- and β-ratios are tightly regulated in hematopoietic cells and DMP1β antagonizes DMP1α transcriptional regulation of ARF resulting in the alteration of cellular control with a gain in proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.